Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1

Conditions

Neoplasms 3Neoplasm Metastasis 2Breast Neoplasms 2

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × AZD 8931 × Clear all
NCT00900627 2016-01-20

THYME

AstraZeneca

Phase 1/2 Completed
330 enrolled 20 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01003158 2014-07-10

Study Assessing Safety and Tolerability of AZD8931 Alone or in Combination With Paclitaxel in Japanese Patients.

AstraZeneca

Phase 1 Completed
17 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00637039 2013-03-12

Study of AZD8931 in Patients With Advanced Solid Malignancies

AstraZeneca

Phase 1 Completed
41 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡